News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
334,923 Results
Type
Article (14443)
Company Profile (66)
Press Release (320414)
Section
Business (103907)
Career Advice (467)
Deals (21512)
Drug Delivery (17)
Drug Development (44239)
Employer Resources (66)
FDA (8277)
Job Trends (9389)
News (179345)
Policy (18721)
Tag
Academia (1738)
Africa (299)
Alabama (27)
Alliances (21908)
Alzheimer's disease (529)
Approvals (8256)
Arizona (42)
Asia (19598)
Australia (2541)
Bankruptcy (187)
Best Places to Work (8309)
Biotechnology (46)
C2C Services and Suppliers (27890)
California (815)
Canada (383)
Cancer (169)
Career advice (399)
CAR-T (25)
Cell therapy (56)
China (47)
Clinical research (34151)
Collaboration (38)
Colorado (36)
Connecticut (32)
COVID-19 (2699)
Cystic fibrosis (26)
Data (93)
Diabetes (28)
Diagnostics (3736)
Earnings (46698)
Employer resources (56)
Europe (38875)
Events (50133)
Executive appointments (38)
FDA (8358)
Florida (134)
Funding (30)
Gene therapy (26)
Georgia (26)
GLP-1 (234)
Government (3353)
Healthcare (12595)
Hotbed/Location (237161)
Illinois (116)
Indiana (67)
Infectious disease (2708)
Inflammatory bowel disease (41)
Interviews (83)
IPO (11415)
Job creations (1145)
Job search strategy (354)
Kansas (53)
Layoffs (150)
Legal (3775)
Liver cancer (35)
Lung cancer (36)
Maine (34)
Management (27)
Maryland (136)
Massachusetts (573)
Medical device (7227)
Medtech (7229)
Mergers & acquisitions (10010)
Metabolic disorders (79)
Michigan (47)
Minnesota (72)
Neuroscience (573)
New Hampshire (36)
New Jersey (299)
New York (269)
NextGen Class of 2024 (4671)
Non-profit (3246)
North Carolina (252)
Northern California (399)
Obesity (47)
Ohio (36)
Opinion (63)
Patents (29)
Pennsylvania (332)
People (27483)
Phase I (10138)
Phase II (14927)
Phase III (12332)
Pipeline (79)
Postmarket research (1234)
Preclinical (3919)
Rare diseases (42)
Real estate (2403)
Recruiting (28)
Regulatory (12193)
Research institute (1556)
Resumes & cover letters (65)
South America (485)
Southern California (352)
Startups (1368)
Texas (83)
United States (3731)
Vaccines (426)
Washington State (170)
Weight loss (33)
Date
Last 7 days (220)
Last 30 days (1298)
Last 365 days (20158)
2024 (13079)
2023 (22599)
2022 (30957)
2021 (35417)
2020 (35796)
2019 (37700)
2018 (23587)
2017 (14343)
2016 (12483)
2015 (16117)
2014 (10938)
2013 (8093)
2012 (9060)
2011 (9951)
2010 (8572)
334,923 Results for "19".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
COVID-19
FDA Limits Use of Invivyd’s COVID-19 Prophylactic as New Variants Dominate
The regulator’s restrictions come as the U.S. is experiencing a surge in cases. Invivyd also announced updated Phase III data for Pemgarda, touting an 84% relative reduction in symptomatic COVID-19.
August 28, 2024
·
2 min read
·
Tristan Manalac
Emergence Of CD19 Targeted Antibodies
CD19, a protein prominently displayed on the surface of B cells, has become a focal point in therapeutic interventions for a spectrum of diseases, particularly cancer.
May 23, 2024
·
2 min read
Deals
GSK Pays $430M Upfront for CureVac’s COVID-19, Flu mRNA Vaccines
GSK on Wednesday restructured its contract with CureVac to gain access to the biotech’s influenza and COVID-19 programs for $430 million upfront and up to $1.13 billion in future payments.
July 3, 2024
·
2 min read
·
Tristan Manalac
Lone Star Bio
Researchers take step toward development of universal COVID-19 antibodies
SARS-CoV-2, the virus that causes COVID-19 disease, continues to evolve and evade current vaccine and therapeutic interventions.
May 30, 2024
·
3 min read
Business
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization for the companies’ Omicron JN.1-adapted monovalent COVID-19 vaccine (COMIRNATY® JN.1) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older.
June 27, 2024
·
24 min read
Drug Development
Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-19 Vaccine
Moderna, Inc. announced that its Phase 3 trial of mRNA-1283, an investigational next-generation COVID-19 vaccine, has met its primary efficacy endpoint, demonstrating non-inferior vaccine efficacy against COVID-19 compared to Spikevax.
June 13, 2024
·
4 min read
Co-Diagnostics, Inc. to Participate at FIME 2024 in Miami Beach, June 19-21
Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company has been invited to participate in the Utah booth at the FIME trade show in Miami Beach, Florida, on June 19-21.
June 18, 2024
·
1 min read
Drug Development
Moderna Gets Win in COVID-19 Patent Dispute with Pfizer, BioNTech
The European Patent Office last week upheld one of Moderna’s key patents, handing the biotech an important victory in its protracted COVID-19 vaccine battle with Pfizer and BioNTech.
May 20, 2024
·
2 min read
·
Tristan Manalac
Drug Development
Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19
Moderna, Inc. announced that its Phase 3 trial of mRNA-1083, an investigational combination vaccine against influenza and COVID-19, has met its primary endpoints, eliciting a higher immune response than the licensed comparator vaccines used in the trial.
June 10, 2024
·
5 min read
Drug Development
Biophytis Presented its Phase 2-3 COVA Study Results in Severe Forms of Covid-19 at the WCID in Paris
Biophytis SA, a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, presented the roll-out and results of its phase 2/3 COVA study in the treatment of severe forms of Covid-19 at the 6th edition of the World Congress on Infectious Diseases, held from June 24 to 26, 2024 in Paris, France.
July 1, 2024
·
4 min read
1 of 33,493
Next